Transaction DateRecipientSharesTypePriceValue
12th August 2020David J Matlin6,900,000Open or private sale$30.05$207,345,000.00
20th July 2020Robert J Hariri15,300Exercise of in-the-money or at-the-money derivatives securities (usually options)$3.57$54,621.00
31st March 2020Eric Zaltas16,529Grant/award etc.$0.00
31st March 2020Victor E Mandel41,322Grant/award etc.$0.00
31st March 2020Louis J. Aronne29,752Grant/award etc.$0.00
31st March 2020Robert J Hariri3,306Grant/award etc.$0.00
31st March 2020Joseph Mannello16,529Open or private purchase$0.00
31st March 2020Christopher C Dewey6,611Open or private purchase$0.00
31st March 2020Andrew Joel Ponte3,306Open or private purchase$0.00
31st March 2020Christopher Pechock45,455Grant/award etc.$0.00
Myos Rens Technology
Myos Rens Technology logo

MYOS RENS Technology, Inc. engages in the discovery, development, and commercialization of advanced nutrition products, functional foods, and other technologies. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk.

Ticker: MYOS
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1402479
Employees: 15
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags